Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare Ozanimod (Zeposia) and Vedolizumab (Entyvio) — clinical data, side effects, and patient experiences.
Zeposia · S1P Receptor Modulator
How it works
S1P receptor 1,5 modulator that reduces circulating lymphocytes by retaining them in lymph nodes.
Approved for
Entyvio · Integrin Inhibitor
How it works
Humanized monoclonal antibody that binds alpha4-beta7 integrin, blocking lymphocyte trafficking to gut-associated lymphoid tissue.
Approved for
Estimated frequency (%) based on clinical trial data
No specific warnings
No head-to-head clinical studies found for Ozanimod vs Vedolizumab.
Ozanimod is a S1P Receptor Modulator, while Vedolizumab belongs to the Integrin Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. Ozanimod is administered via Oral, whereas Vedolizumab uses Intravenous or Subcutaneous. Route of administration can affect onset of action and patient adherence.
Both medications are approved for Ulcerative Colitis. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
Vedolizumab carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.